Alector, Inc. (ALEC) research
Alector, Inc.- Sector
- Biotechnology
- Last price
- $1.99
- As of
Kresmion compiles this page from ALEC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Alector, Inc. (ALEC): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-05.
As of . Source: SEC EDGAR filings for ALEC. Method and limitations.
Share the ALEC intelligence card
See the full ALEC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ALEC on one page. Preview it with sample data, then open it live with a free account.
Preview the ALEC dossierActive signals for ALEC
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +104% to ALEC (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +631% to ALEC (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 67% of ALEC (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 9.7%, EPS $-0.21 vs $-0.2326 estimate
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +247% to ALEC (2026Q1)
FREE, NO ACCOUNT
Every signal on ALEC, as it fires
You are seeing 5 of 9 signals recorded on ALEC since 2026-05-30.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ALEC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 014442107 · 2026Q2 | $5.9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 014442107 · 2026Q2 | $4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 014442107 · 2026Q2 | $2.1M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 014442107 · 2026Q2 | $1.9M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 014442107 · 2026Q2 | $786K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 014442107 · 2026Q2 | $54K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ALEC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ALEC against its peers
ALEC's operating margin of -741.3% ranks in the 25th percentile of 17 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ALEC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 21.0M USD | 26.4M USD | 45 | 18 |
| Operating margin | -741.3% | -221.7% | 25 | 17 |
| Net margin | -679.2% | -49.9% | 14 | 17 |
| Return on equity | -466.3% | -37.6% | 6 | 23 |
| P / E | n/a | 5.0x | n/a | 5 |
Peers (24): ELDN, NAUT, ACOG, XGN, TRDA, WHWK, NGEN, ADAG, ANTX, PLX, ORMP, CGEN, CUE, NAGE, NKTX, RNAC, KROS, MSLE, CNTN, CHRS, MGNX, PYXS, ORGO, LYEL. Left out: VRXA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ALEC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ALEC on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ALEC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.